<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Role of muscarinic antagonist therapy in COPD</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Role of muscarinic antagonist therapy in COPD</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Role of muscarinic antagonist therapy in COPD</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raed A Dweik, MD, FACP, FCCP, FRCP(C), FCCM, FAHA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James K Stoller, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Muscarinic antagonists (also known as anticholinergic agents) are effective bronchodilators used in the treatment of chronic obstructive pulmonary disease (COPD), used to alleviate dyspnea and improve exercise tolerance.</p><p>This topic will review the pharmacology of muscarinic antagonists and their role in the treatment of COPD. The management of acute exacerbations and the approach to the treatment of COPD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a> and  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">HISTORY OF BELLADONNA ALKALOIDS</span><span class="headingEndMark"> — </span>Pharmacologically active anticholinergic alkaloids exist in the roots, seeds, and leaves of a variety of belladonna plants [<a href="#rid1">1</a>]. The most important of these naturally occurring alkaloids are <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> and <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">scopolamine</a>.</p><p><em>Atropa belladonna</em>, the deadly nightshade, contains mainly the alkaloid <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>. The same alkaloid is present in <em>Datura stramonium</em>, known as Jamestown or jimson weed, stinkweed, thorn-apple, and devil's apple. The alkaloid <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">scopolamine</a> (hyoscine) is found chiefly in the plants <em>Hyoscyamus niger</em> (henbane) and <em>Scopolia carniolica</em>.</p><p>The use of extracts from these plants for the relief of respiratory symptoms and bronchospasm originated thousands of years ago in India and was introduced into Western medicine by British colonists in the early 19th century [<a href="#rid1">1</a>]. <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">Atropine</a> was then isolated in a pure form by Mein in 1831. In 1867, Bezold and Bloebaum showed that atropine blocked the cardiac effects of vagal stimulation, and five years later Heidenhain found that it prevented salivary secretion produced by stimulation of the chorda tympani. In 1859, it was reported that a severe asthma attack was successfully treated by injecting atropine into the vagus nerve [<a href="#rid2">2</a>].</p><p>Smoke from the leaves of these plants became the preparation of choice for relief of bronchospasm; inhalational and systemic preparations of <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> were soon available for the treatment of asthma. With the introduction of <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a> and <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> during the 20th century, the use of atropine and related substances for relief of bronchospasm declined. Anticholinergic therapy has again come to the forefront of bronchodilator therapy with the introduction of the synthetic quaternary derivatives of atropine, including <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> bromide and <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> bromide [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PHYSIOLOGY AND PHARMACOLOGY</span><span class="headingEndMark"> — </span>The parasympathetic nervous system plays a major role in regulating bronchomotor tone. The bulk of autonomic nerves in the human airways are branches of the vagus nerve, whose efferent preganglionic fibers enter the lung at the hilum and travel along the airways into the lung [<a href="#rid3">3</a>]. A diverse set of stimuli can cause a reflex increase in parasympathetic activity that contributes to bronchoconstriction. Acetylcholine (ACh) is the endogenous neurotransmitter at cholinergic nerve endings, and its actions are mediated through nicotinic and muscarinic cholinergic receptors. The figure outlines the role of nicotinic and muscarinic receptors in cholinergic transmission in the airway  (<a class="graphic graphic_figure graphicRef58052" href="/z/d/graphic/58052.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H4"><span class="h2">Nicotinic receptors</span><span class="headingEndMark"> — </span>Nicotinic receptors are located on ganglionic neurons and are activated by ACh released from preganglionic vagal fibers  (<a class="graphic graphic_figure graphicRef58052" href="/z/d/graphic/58052.html" rel="external">figure 1</a>). These receptors are stimulated by nicotinic agonists and inhibited by nicotinic antagonists like hexamethonium. They are not significantly affected by currently available muscarinic antagonist medications [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Muscarinic receptors</span><span class="headingEndMark"> — </span>Muscarinic receptors are found primarily on the autonomic effector cells that are innervated by postganglionic parasympathetic nerves. There are at least five subtypes of muscarinic receptors [<a href="#rid5">5</a>]. At least three of these are expressed in the lung  (<a class="graphic graphic_table graphicRef79055" href="/z/d/graphic/79055.html" rel="external">table 1</a>) [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>M1 receptors are present on peribronchial ganglion cells where the preganglionic nerves transmit signals to the postganglionic nerves</p><p class="bulletIndent1"><span class="glyph">●</span>M2 receptors are present on the postganglionic nerves</p><p class="bulletIndent1"><span class="glyph">●</span>M3 receptors are present on smooth muscle</p><p></p><p>M1 and M3 receptors mediate the parasympathetic bronchoconstrictive effect of the vagus nerve. Vagal fibers synapse and activate nicotinic and M1 muscarinic receptors in parasympathetic ganglia present in the airway wall. Short postganglionic fibers release ACh, which acts on M3 muscarinic receptors in airway smooth muscle. The submucosal glands are also innervated by parasympathetic neurons and have predominantly M3 receptors.</p><p>The activation of M1 and M3 receptors by ACh and its analogs stimulates secretion by tracheobronchial glands and causes bronchoconstriction. On the other hand, activation of M2 receptors limits further production of ACh and protects against parasympathetic-mediated bronchoconstriction [<a href="#rid1">1,5</a>]. Based upon this information, an ideal muscarinic antagonist for treating COPD would inhibit only the M1 and M3 receptors and spare the M2 receptors.</p><p><a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">Atropine</a> (the prototype of muscarinic receptor antagonists) prevents the effects of ACh by competitively blocking its binding to muscarinic receptors in the CNS, peripheral ganglia, and at neuroeffector sites on smooth muscle, cardiac muscle, and secretory glands [<a href="#rid1">1</a>]. Atropine inhibits secretions of the nose, mouth, pharynx, and bronchi and thus causes dryness of the mucous membranes of the respiratory tract. This action is especially marked if secretion is excessive and is the basis for the use of atropine and <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">scopolamine</a> in preanesthetic medication. This depression of mucous secretion and the inhibition of mucociliary clearance, however, are undesirable side effects of atropine in patients with airway disease [<a href="#rid6">6</a>].</p><p><a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">Atropine</a> is particularly effective against bronchoconstriction produced by parasympathomimetic drugs such as <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a>; it also partially antagonizes bronchoconstriction induced by histamine and bradykinin. In general, however, muscarinic receptor antagonists cause little blockade of the effects of ACh at nicotinic receptor sites. As a result, extremely high doses of atropine or related drugs are required to produce any degree of blockade of the predominantly nicotinic receptors at the neuromuscular junction [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Tertiary versus quaternary muscarinic antagonists</span><span class="headingEndMark"> — </span>Quaternary ammonium drugs (such as <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>) are synthetic derivatives of the naturally occurring tertiary ammonium compounds (such as <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>)  (<a class="graphic graphic_figure graphicRef55857" href="/z/d/graphic/55857.html" rel="external">figure 2</a>).</p><p>The structure of the quaternary ammonium compounds  (<a class="graphic graphic_figure graphicRef55857" href="/z/d/graphic/55857.html" rel="external">figure 2</a>) renders them freely soluble in water but insoluble in lipids; it is therefore difficult for these compounds to cross biologic barriers that can be easily crossed by the tertiary ammonium compounds like <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>. Most of the pharmacologic properties that distinguish quaternary ammonium compounds from atropine are due to this feature [<a href="#rid1">1,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The tertiary ammonium compounds are lipid-soluble, easily absorbed, and can cause significant side effects, including tachycardia, dry mouth, flushing of the skin, blurred vision, and mood changes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since compounds with a quaternary ammonium structure are poorly absorbed after oral administration, they cause fewer side effects</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Quaternary compounds generally exhibit a greater degree of nicotinic blocking activity and consequently are likely to interfere with neuromuscular transmission in doses that more closely approximate those that cause muscarinic block.</p><p></p><p><a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">Ipratropium</a> bromide produces effects similar to <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> when each agent is administered parenterally [<a href="#rid1">1,6</a>]. These include bronchodilation, tachycardia, and inhibition of salivary secretion. Unlike atropine, though, ipratropium lacks appreciable effect on the central nervous system (CNS), is poorly absorbed from the lungs or the gastrointestinal tract, and does not inhibit mucociliary clearance [<a href="#rid1">1,6</a>]. The use of ipratropium in patients with COPD therefore avoids the increased accumulation of lower airway secretions and the antagonism of beta-adrenergic agonist-induced enhancement of mucociliary clearance that is encountered with atropine.</p><p>Even when <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> bromide is administered in amounts many times the recommended dosage, little or no change occurs in heart rate, blood pressure, bladder function, intraocular pressure, or pupillary diameter [<a href="#rid6">6</a>]. This selectivity results from the very inefficient absorption of the drug from airway or gastrointestinal mucosa.</p><p class="headingAnchor" id="H7"><span class="h1">IPRATROPIUM</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">Ipratropium</a> bromide (Atrovent) is available in a metered dose inhaler (MDI) form. Each actuation of the MDI provides 17 mcg of ipratropium bromide, and each canister contains 200 inhalations. Prior to initial use of the MDI formulation, the inhaler should be actuated into the air twice; this step should be repeated if the inhaler is not used for more than three days. A 0.02 percent solution for nebulized administration is also available.</p><p class="headingAnchor" id="H8"><span class="h2">Dose</span><span class="headingEndMark"> — </span>The recommended dose from the MDI is two puffs four times daily, usually taken as needed. For patients with a COPD exacerbation requiring emergency department or hospital based care, <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> can be increased to a higher dose (eg, two inhalations every hour for two to three doses and then every two to four hours, or four inhalations every four hours), if response to the lower dose is insufficient [<a href="#rid7">7</a>].</p><p><a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">Ipratropium</a> can also be administered by nebulization. Ipratropium solution comes as 0.5 mg/2.5 mL (0.02 percent) vials that can be given by nebulization every four to six hours [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">Ipratropium</a> has been shown to alleviate dyspnea, increase exercise tolerance, and improve gas exchange in patients with COPD [<a href="#rid8">8</a>]. Ipratropium, however, does not have anti-inflammatory properties and does not alter the natural history of the disease in terms of lung function or mortality [<a href="#rid8">8-10</a>]. Tachyphylaxis to ipratropium has not been demonstrated, and thus its efficacy is not blunted over years of regular use [<a href="#rid6">6</a>].</p><p>The Lung Health Study prospectively evaluated the effect of smoking cessation with or without <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> therapy on the decline of lung function in 5887 male and female smokers with COPD [<a href="#rid9">9</a>]. In this landmark study, ipratropium was chosen as the bronchodilator of choice because of its low frequency of side effects, relatively long duration of action, and demonstrated bronchodilator efficacy in patients with COPD [<a href="#rid6">6,9,11</a>]. Results were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The regular use of inhaled <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> bromide (two puffs three times daily from a metered dose inhaler) produced an increase in FEV<sub>1</sub> that was evident at the end of the first year. This relative improvement was maintained for the succeeding four years  (<a class="graphic graphic_figure graphicRef56320" href="/z/d/graphic/56320.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The improvement in lung function appeared to reverse within a few weeks of stopping the <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>.</p><p></p><p>These results reflect the relatively short term, pharmacologically mediated change in lung function attributable to the bronchodilator, and support the use of bronchodilators for symptomatic benefit, including relief of dyspnea and improvement in exercise tolerance. By comparison, no treatment is needed in asymptomatic patients, as therapy does not alter the natural history of the disorder.</p><p class="headingAnchor" id="H10"><span class="h2">Ipratropium versus beta-agonists</span><span class="headingEndMark"> — </span>In COPD, <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> has been shown to be superior to the beta-adrenergic agonists in both short- and long-term studies. As an example, in a multicenter, randomized trial of 260 patients with COPD but no asthma or atopy, ipratropium was more potent at its peak effect and was longer acting than <a class="drug_supplemental_data drug_dxy_dosage_form" data-topicid="9619" href="/contents/null?topicRef=1450&amp;source=see_link">metaproterenol</a> [<a href="#rid11">11</a>]  (<a class="graphic graphic_figure graphicRef73667" href="/z/d/graphic/73667.html" rel="external">figure 4</a>). Similar findings were also reported for nebulized ipratropium bromide [<a href="#rid12">12</a>]. In addition, some studies have shown that ipratropium bromide produced significant bronchodilation in patients who did not respond to inhaled sympathomimetics [<a href="#rid12">12</a>].</p><p><a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">Ipratropium</a> therapy may also result in an improvement in the quality of life of patients with COPD. In a multicenter, randomized trial of 223 patients with COPD, the efficacy of nebulized ipratropium (500 mcg) was compared to nebulized <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> (2.5 mg) (each taken three times daily for up to 83 days) [<a href="#rid13">13</a>]. Although clinical improvement was noted in both groups, the ipratropium bromide group had a greater symptomatic benefit and scored higher on quality of life questionnaires.</p><p>Although the side effects of inhaled beta-2 agonists are generally minor, they may produce troublesome tremor in the dosages required to produce bronchodilation in COPD. In addition, beta-2 agonist use in patients with COPD may be accompanied by pulmonary vasodilation, which may worsen ventilation-perfusion matching and result in a slight fall in arterial PaO2 [<a href="#rid14">14</a>]. The beneficial effects of <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> bromide combined with its minimal side effects make this agent the preferred bronchodilator for COPD in the ambulatory setting.</p><p>Fewer studies are available in acute exacerbations of COPD. (See  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Combination therapy</span><span class="headingEndMark"> — </span>The administration of a combination of antimuscarinic and beta-agonist agents generally results in greater bronchodilation than does the administration of single agents in patients with COPD [<a href="#rid15">15,16</a>]. As an example, one crossover trial of 863 patients found that combination therapy with nebulized <a class="drug drug_general" data-topicid="8772" href="/z/d/drug information/8772.html" rel="external">ipratropium-albuterol</a> resulted in a peak forced expiratory volume in one second (FEV<sub>1</sub>) that was 24 percent higher than that achieved by <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> alone, and 37 percent greater than that achieved with <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> monotherapy [<a href="#rid16">16</a>]. In patients with COPD, this combination offers a potential therapeutic advantage over albuterol alone without a risk of increased side effects. (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management", section on 'Use of dual bronchodilator therapy'</a>.)</p><p>Often the agents are administered in a fixed combination, such as the <a class="drug drug_general" data-topicid="8772" href="/z/d/drug information/8772.html" rel="external">ipratropium-albuterol</a> soft mist inhaler, one inhalation four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed six in 24 hours. When <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> and <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> are given separately, there is little evidence to indicate in which sequence to give the two drugs and whether they should be given in immediate sequence or should be separated by an interval [<a href="#rid6">6</a>].</p><p>Several physiologic reasons exist for the potential benefit of combination therapy with <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> and a beta-agonist:</p><p class="bulletIndent1"><span class="glyph">●</span>Muscarinic antagonists act predominantly on the proximal large airways, while sympathomimetics act on the more distal small airways.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The two classes of medications cause bronchodilation via different mechanisms: Beta-agonists are thought to cause bronchodilation by directly acting on muscle, and <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> causes bronchodilation by reducing cholinergic tone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coadministration of adrenergic and muscarinic antagonists provides the rapid onset of action of the former and the sustained activity of the latter; their combined effect is present at intermediate times.</p><p></p><p class="headingAnchor" id="H12"><span class="h1">TIOTROPIUM</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">Tiotropium</a>  (<a class="graphic graphic_figure graphicRef55857" href="/z/d/graphic/55857.html" rel="external">figure 2</a>) is a long-acting muscarinic antagonist (LAMA) with M1 and M3 selectivity  (<a class="graphic graphic_table graphicRef79055" href="/z/d/graphic/79055.html" rel="external">table 1</a>) (see <a class="local">'Muscarinic receptors'</a> above) [<a href="#rid17">17,18</a>]. Tiotropium binds to all three muscarinic receptors, but it comes off the M2 receptor rather rapidly without affecting the inhibition of M1 and M3 receptors. Tiotropium may therefore have a theoretical advantage over <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> bromide since inhibition of the M2 receptor would have a bronchoconstrictive effect.</p><p>The dry powder preparation is administered via a capsule inhaler device (HandiHaler), 18 mcg once daily  (<a class="graphic graphic_picture graphicRef57922" href="/z/d/graphic/57922.html" rel="external">picture 1</a>). The soft mist preparation (Respimat) is administered as two inhalations of 2.5 mcg (5 mcg total) once daily  (<a class="graphic graphic_picture graphicRef91634" href="/z/d/graphic/91634.html" rel="external">picture 2</a> and <a class="graphic graphic_table graphicRef93600" href="/z/d/graphic/93600.html" rel="external">table 2</a>). Depending on the country, one or both of these inhaler types may be available.</p><p><a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">Tiotropium</a> is longer acting than <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> and allows a more convenient dosing schedule for patients with COPD [<a href="#rid19">19-21</a>]. One study randomized 288 patients with severe COPD to receive either tiotropium once per day or ipratropium four times per day [<a href="#rid22">22</a>]. Significantly greater bronchodilation was achieved and significantly less <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> was used in the tiotropium group. </p><p>Continuous therapy with <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> appears to be well tolerated and is associated with decreased dyspnea, improved quality of life, fewer acute exacerbations, a reduction in hyperinflation, and improved overnight arterial oxygen saturation compared to placebo [<a href="#rid23">23-31</a>]. A meta-analysis of 22 trials with 23,309 participants found that tiotropium therapy resulted in a significantly improved mean quality of life (mean difference [MD] -2.89, 95% CI -3.35 to -2.44) and significantly reduced the number of participants suffering from exacerbations (OR 0.78, 95% CI 0.70-0.87) [<a href="#rid30">30</a>]. In this analysis, the number needed to treat to benefit (NNTB) was 16 to prevent one exacerbation. Tiotropium also reduced exacerbations leading to hospitalization but no significant difference was found for hospitalization of any cause or mortality.</p><p>The lack of an immediate bronchodilator response to <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> does not correlate with the results of extended therapy. This was demonstrated in a large randomized controlled trial comparing one year of therapy with tiotropium to placebo [<a href="#rid32">32</a>]. The presence or absence of a bronchodilator response on the first day of treatment did not predict long-term outcome, and patients treated with tiotropium had improved spirometry and less subjective dyspnea than control patients regardless of the response to the first dose.</p><p>In a systematic review that compared <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> with <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> in patients with COPD (n = 1073), tiotropium was associated with improved lung function, fewer hospitalizations, fewer exacerbations of COPD, and improved quality of life [<a href="#rid33">33</a>]. This observation supports guideline recommendations for use of a long-acting bronchodilator in patients whose symptoms are not controlled with intermittent use of a short-acting bronchodilator.</p><p><a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">Tiotropium</a>, like <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>, appears to provide superior bronchodilation and improvements in dyspnea when compared with long-acting beta-agonists in patients with stable disease [<a href="#rid34">34-36</a>]. This was demonstrated in a large three-armed trial comparing tiotropium with the long-acting beta-agonist <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> and placebo in over 1200 patients with COPD. Therapy with tiotropium resulted in a significant delay in the time until first exacerbation, and fewer exacerbations per year, than treatment with salmeterol or placebo [<a href="#rid35">35</a>].</p><p>Over the long-term, <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> improves lung function and quality of life, and also decreases the risk of exacerbations, but does not reduce the rate of decline in forced expiratory volume in one second (FEV<sub>1</sub>) [<a href="#rid37">37</a>]. This was demonstrated in a randomized four year trial, Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT), which compared inhaled tiotropium to placebo. Patients were allowed to take other respiratory medications, as needed. (See <a class="local">'Potential risks'</a> below.)</p><p>A further analysis of the UPLIFT trial found that the benefit of <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> (relative to placebo) on pre and post bronchodilator FEV1, exacerbation risk, and quality of life was present irrespective of smoking status, although the magnitude of the benefit varied among current smokers, intermittent smokers, and continuing ex-smokers [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H3755024"><span class="h1">UMECLIDINIUM</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">Umeclidinium</a> is a long-acting muscarinic antagonist (LAMA) that acts preferentially on the muscarinic M3 receptor, similar to <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>. Bronchodilation peaks at three hours after a dose and is sustained for 24 hours [<a href="#rid39">39</a>]. The long duration of action is attributable, at least in part, to prolonged residence of the molecule on the M3 receptor.</p><p>In a 28 day randomized trial, three once daily doses of <a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">umeclidinium</a> (125 mcg, 250 mcg, 500 mcg) were compared with placebo [<a href="#rid39">39</a>]. All three doses of umeclidinium significantly increased trough forced expiratory volume in one second (FEV<sub>1</sub>) (150 to 160 mL) at 24 hours after the last dose on days 2, 14, 28, and 29, and also reduced rescue salbutamol (<a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) use during the study. Overall, adverse events in the 125 mcg and 250 mcg groups were not different from placebo, but were increased in the 500 mcg group. Cough and headache were increased in frequency at the higher doses.</p><p><a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">Umeclidinium</a> is available in a combination inhaler, <a class="drug drug_general" data-topicid="91900" href="/z/d/drug information/91900.html" rel="external">umeclidinium-vilanterol</a> (62.5 mcg/25 mcg), that is approved for use in COPD. The umeclidinium dose in this inhaler is lower than that used in the dose-ranging study described above. (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management", section on 'Long-acting muscarinic antagonists'</a>.)</p><p class="headingAnchor" id="H1814588"><span class="h1">ACLIDINIUM</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">Aclidinium</a> bromide is a long-acting muscarinic antagonist (LAMA) that selectively inhibits the M3 muscarinic receptor [<a href="#rid40">40-43</a>]. Aclidinium is longer acting than <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>, but shorter acting than <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>. It is administered via a dry powder inhaler (Tudorza Pressair) at a dose of 400 mcg twice daily  (<a class="graphic graphic_picture graphicRef57922" href="/z/d/graphic/57922.html" rel="external">picture 1</a>). It was initially developed as a once daily medication, but further study showed better efficacy with the twice daily dosing schedule. (See <a class="local">'Muscarinic receptors'</a> above.)</p><p>Support for the use of <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">aclidinium</a> in stable chronic obstructive pulmonary disease (COPD) comes from several trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 24-week trial, patients with COPD and moderate to severe airflow limitation (forced expiratory volume in one second [FEV<sub>1</sub>] &lt;80 percent predicted) were randomly assigned to twice-daily <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">aclidinium</a> (200 mcg or 400 mcg) or placebo [<a href="#rid40">40</a>]. Significant improvements in trough and peak FEV<sub>1</sub>were noted with both doses of aclidinium and peak FEV<sub>1</sub> improvements in week 24 were comparable with day one. Health status assessed by questionnaire and dyspnea also improved relative to placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a small trial, <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">aclidinium</a> 400 mcg twice daily was compared with <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> 18 mcg once daily [<a href="#rid44">44</a>]. With both medications, improvements in FEV<sub>1</sub> were greater than with placebo but not significantly different from each other.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an unpublished trial, <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">aclidinium</a> 400 mcg twice daily was compared with the long-acting beta-agonist <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> 12 mcg twice daily in patients with COPD and moderate to severe airflow limitation (FEV<sub>1</sub> &lt;80 percent) [<a href="#rid45">45</a>]. The trough and peak FEV<sub>1</sub> values were not significantly different between these groups.</p><p></p><p>Larger studies with longer treatment durations are needed to provide meaningful comparisons between <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">aclidinium</a>, <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>, and the long-acting beta-agonists [<a href="#rid46">46</a>].</p><p><a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">Aclidinium</a> is not appropriate for acute relief of dyspnea due to bronchoconstriction and has not been studied in subjects younger than 18.</p><p>The most common adverse effects (with a frequency greater than placebo) in clinical trials were headache (6.6 versus 5 percent), nasopharyngitis (5.5 versus 3.9 percent), and cough (3 versus 2.2 percent) [<a href="#rid45">45</a>]. Anticholinergic side effects, such as urinary retention, dry mouth, and constipation, were not different from placebo in clinical trials including 2717 patients on twice daily dosing regimens [<a href="#rid40">40,45</a>].</p><p class="headingAnchor" id="H89640776"><span class="h1">GLYCOPYRRONIUM</span><span class="headingEndMark"> — </span>Glycopyrronium, known by the generic name <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a> in the United States, is a long-acting muscarinic antagonist (LAMA) that selectively inhibits muscarinic receptors in bronchial smooth muscle with greater affinity for M1 and M3 than M2 [<a href="#rid47">47</a>]. (See <a class="local">'Muscarinic receptors'</a> above.)</p><p><a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">Glycopyrronium</a> is administered via dry powder inhaler, one capsule for inhalation (50 mcg/capsule) once daily in Canada and Europe.</p><p>Depending on the country, the dose is variably expressed as the glycopyrronium or <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a> base or bromide salt  (<a class="graphic graphic_table graphicRef105687" href="/z/d/graphic/105687.html" rel="external">table 3</a>). Evidence in favor of efficacy in COPD includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 26 week trial, 822 subjects with moderate-to-severe chronic obstructive pulmonary disease (COPD) were randomly assigned to <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrronium</a> 50 micrograms by oral inhalation once daily or placebo [<a href="#rid48">48</a>]. The trough forced expiratory volume in one second (FEV<sub>1</sub>), assessed at 12 weeks, was significantly higher (least squares mean treatment difference of 108 mL) in the glycopyrronium group. Three patients in the glycopyrronium group had serious atrial fibrillation (AF) events, although two had a prior history of AF. No patients on placebo had AF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 52 week trial, 1086 subjects with moderate-to-severe COPD were randomly assigned to once daily inhaled <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrronium</a>, placebo, or open label <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> 18 micrograms [<a href="#rid49">49</a>]. At week 12, the trough FEV<sub>1</sub> was increased over placebo by 97 mL (95% CI 64.6-130.2) with glycopyrronium and 83 mL (95% CI 45.6-121.4) with tiotropium. Glycopyrronium was also associated with significant improvement in dyspnea and reduction in exacerbations relative to placebo. AF occurred in four patients (0.8 percent) in the glycopyrronium group and none in the placebo or tiotropium groups.</p><p></p><p>Additional, larger studies are needed to ascertain the safety of long-term inhaled <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrronium</a> and to provide meaningful efficacy and safety comparisons with the other long-acting muscarinic antagonists and long-acting beta-agonists.</p><p>The most commonly reported adverse effects with inhaled <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrronium</a> are dry mouth (2 percent of glycopyrronium recipients versus 1 percent of placebo), urinary tract infection (1.77 versus 1.87 percent), and constipation (1 versus 1.5 percent) [<a href="#rid47">47</a>]. In a trial that compared glycopyrronium with <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>, dry mouth was slightly more common with inhaled glycopyrronium than tiotropium, but urinary infection was slightly more common with tiotropium than glycopyrronium [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H4147142966"><span class="h1">REVEFENACIN</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="119622" href="/z/d/drug information/119622.html" rel="external">Revefenacin</a> is a long-acting muscarinic antagonist (LAMA) with broad affinity for all muscarinic receptors M1 to M5; it exerts its bronchodilating effects through prolonged attachment to the M3 receptor on airways smooth muscle [<a href="#rid50">50,51</a>]. Revefenacin is approved by the US Food and Drug Administration (FDA) for maintenance treatment of chronic obstructive pulmonary disease (COPD) at a once daily dose of 175 mcg/3 mL, administered via a standard jet nebulizer [<a href="#rid52">52</a>]. It is not indicated for relief of acute bronchoconstriction. Given the time needed for a nebulizer treatment (&gt;8 minutes), this medication is typically reserved for patients who have difficulty with the technique of soft mist or dry powder formulations of the other LAMAs.</p><p>In two randomized trials that included 395 patients with moderate to severe COPD (mean forced expiratory volume in one second [FEV<sub>1</sub>] 55 percent of predicted), <a class="drug drug_general" data-topicid="119622" href="/z/d/drug information/119622.html" rel="external">revefenacin</a> 175 mcg increased mean FEV<sub>1</sub> from baseline to trough at day 85 by 146 mL (95% CI 103.7 to 188.8 mL) and 147 mL (95% CI 97 to 197.1 mL) [<a href="#rid52">52-54</a>]. In the placebo groups, approximately 37 percent were also taking a long-acting beta-agonist (LABA) or inhaled glucocorticoid/LABA.</p><p>Use of <a class="drug drug_general" data-topicid="119622" href="/z/d/drug information/119622.html" rel="external">revefenacin</a> should be avoided in patients with hepatic impairment and has not been studied in patients with endstage renal disease. Revefenacin can exacerbate narrow angle glaucoma and worsen urinary retention.</p><p class="headingAnchor" id="H639301157"><span class="h1">COMBINATION LAMA-LABA</span><span class="headingEndMark"> — </span>A number of single inhaler preparations are available combining long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA). These agents are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management", section on 'Use of dual bronchodilator therapy'</a> and  <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">"Stable COPD: Follow-up pharmacologic management"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">OTHER AGENTS</span><span class="headingEndMark"> — </span>Several additional quaternary muscarinic antagonists are being evaluated for a potential role in the treatment of patients with chronic obstructive pulmonary disease (COPD):</p><p class="bulletIndent1"><span class="glyph">●</span>Oxitropium bromide (Ba 253 Br) is an effective muscarinic antagonist bronchodilator that inhibits all three muscarinic airway receptors. It may be a more potent bronchodilator than <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> at lower doses, but there is no difference in maximal response between the two [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Telenzepine is an experimental M1-selective muscarinic receptor antagonist that has been found to improve lung function in patients with nocturnal asthma but not in those with COPD [<a href="#rid56">56,57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tiquizium is another experimental antimuscarinic agent that inhibits all three muscarinic receptor subtypes. It has been shown to be an effective bronchodilator in both animals and humans [<a href="#rid58">58</a>].</p><p></p><p class="headingAnchor" id="H14"><span class="h1">POTENTIAL RISKS</span><span class="headingEndMark"> — </span>Systemic absorption of <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> and the long-acting muscarinic antagonists (LAMA) from the mouth and gastrointestinal tract is low, although some absorption from the lung does occur. Systemic bioavailability of <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> is estimated to be about 20 to 25 percent, while bioavailability of <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">aclidinium</a> is less than 5 percent [<a href="#rid59">59,60</a>].</p><p class="headingAnchor" id="H91301605"><span class="h2">Cardiovascular effects</span><span class="headingEndMark"> — </span>Despite the minimal impact of <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> and long-acting muscarinic antagonists (LAMAs) on heart rate and blood pressure, concern has been raised regarding possible adverse cardiovascular effects of these agents in patients with COPD [<a href="#rid37">37,61-65</a>]. Conflicting findings have been reported in randomized trials and meta-analyses [<a href="#rid37">37,61-64,66-68</a>].</p><p>Evidence against a significant adverse cardiovascular impact comes from three large randomized trials that adjudicated adverse cardiovascular events:</p><p class="bulletIndent1"><span class="glyph">●</span>The Understanding Potential Long-Term Impacts on Function with <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">Tiotropium</a> (UPLIFT) trial randomized 5993 patients to either tiotropium or placebo in addition to other, unrestricted respiratory medications for four years. A significantly lower rate of cardiac adverse events was found in the tiotropium group (RR 0.84 [95% CI 0.73-0.98]) [<a href="#rid37">37</a>]. Cardiac mortality was also decreased in the tiotropium group (HR 0.86 [95% CI 0.75-0.99]) [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of cardiovascular events was further examined using the clinical trial safety database for <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>, which monitored 19,545 patients with moderate to severe COPD (including the UPLIFT data), who were randomly assigned to tiotropium or placebo in a total of 30 trials [<a href="#rid68">68</a>]. No increase in all-cause mortality, cardiovascular mortality, or cardiovascular events was found in the tiotropium group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the randomized ASCENT trial that included 3589 subjects with moderate to very severe COPD and a history of cardiovascular disease or two atherothrombotic risk factors, the risk of a major adverse cardiovascular event during the three years of the trial was not significantly different between the <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">aclidinium</a> and placebo groups (3.9 versus 4.2 percent, HR 0.89, 1-sided 97.5% CI 0-1.23) [<a href="#rid70">70</a>]. Approximately 60 percent of subjects were taking an inhaled glucocorticoid and a LABA.</p><p></p><p>Evidence suggesting increased cardiovascular adverse effects includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 17 randomized trials enrolling nearly 15,000 patients, but not including the UPLIFT or ASCENT trials, the use of <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> or <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> for more than 30 days significantly increased the risk of myocardial infarction (RR 1.53 [95% CI, 1.05 to 2.23]) and cardiovascular death (RR 1.80 [95% CI, 1.17 to 2.77]) [<a href="#rid61">61</a>]. However, the trials did not have prespecified and adjudicated cardiovascular endpoints.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The potential effect of <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> on cardiovascular events was examined in a cohort study of 82,717 United States veterans with COPD who were followed from 1999 to 2002 [<a href="#rid67">67</a>]. The hazard ratio for cardiovascular events among patients who had four or fewer 30-day prescriptions for ipratropium was 1.40 [95% CI 1.30-1.51], and the hazard ratio among those with more than four 30 day prescriptions was 1.23 [95% CI 1.13-1.36]. The case cohort design results in several limitations on the interpretation of the findings.</p><p></p><p>Further data on the safety of <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> bromide are needed from randomized trials in which cardiovascular endpoints are specifically sought and defined. In the meantime, we continue to advise an individualized assessment of potential cardiovascular risk against the <strong>known</strong> benefits of inhaled muscarinic antagonists (eg, reduced frequency of exacerbations, fewer hospitalizations, and improved dyspnea).</p><p class="headingAnchor" id="H283474958"><span class="h2">Mortality</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">Tiotropium</a> is available as a dry powder inhaler (Spiriva HandiHaler) or a soft mist inhaler (Spiriva Respimat), depending upon the geographic location. A systematic review raised concern about a possible increase in mortality associated with the tiotropium soft mist inhaler in patients with COPD [<a href="#rid71">71</a>]. A follow-up meta-analysis that included the UPLIFT trial described above was reassuring in terms of the safety of tiotropium by dry powder inhaler; fewer deaths occurred in the tiotropium dry powder inhaler group (Peto OR 0.92, 95% CI 0.80-1.05) than in the placebo group (yearly rate 2.8 percent) [<a href="#rid30">30</a>]. In contrast, there were more deaths in the tiotropium soft mist inhaler subgroup analysis (Peto OR 1.47, 95% CI 1.04-2.08) than with placebo (yearly rate 1.8 percent). However, methodologic concerns, such as uneven study discontinuation rates, limited the conclusions that could be drawn. </p><p>Subsequently, the <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">TIOtropium</a> Safety and Performance In Respimat (TIOSPIR) trial has provided the most reassuring data. In this trial, 17,135 patients with COPD were randomly assigned to Respimat 2.5 or 5 mcg/day or dry powder inhaler 18 mcg/day [<a href="#rid72">72</a>]. After a mean follow-up of 2.3 years, the risk of mortality did not differ in the Respimat groups; the hazard ratios were (HR 1.00, 95% CI 0.87-1.14) and (HR 0.96, 95% CI 0.84-1.09) for the 2.5 and 5 mcg doses of Respimat versus the dry powder inhaler. While patients with cardiac arrhythmia, ischemic heart disease, and coronary heart disease were included, those with unstable cardiovascular conditions (class III or IV heart failure, myocardial infarction in the prior six months, unstable or life-threatening arrhythmias that required an intervention or change in drug therapy within 12 months), or moderate or severe renal failure were excluded [<a href="#rid73">73</a>]. Thus, the safety of the tiotropium soft mist inhaler in these latter groups has not been determined.</p><p class="headingAnchor" id="H91301509"><span class="h2">Acute urinary retention</span><span class="headingEndMark"> — </span>Systemic absorption of inhaled muscarinic antagonists has the potential to increase the risk of acute urinary retention in susceptible patients such as those with benign prostatic hypertrophy (BPH) or lower urinary tract symptoms [<a href="#rid62">62,74-76</a>]. Studies addressing this concern have yielded conflicting results.</p><p>Studies suggesting an increased risk of urinary retention include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a pooled analysis of 19 randomized trials, the relative risk of symptoms of urinary retention was 10.93 (95% CI 1.26-94.88) [<a href="#rid62">62</a>]. However, the severity of the urinary symptoms was not delineated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A nested case control study of 565,073 older adults with COPD examined the risk of acute urinary retention associated with use of inhaled muscarinic antagonists [<a href="#rid74">74</a>]. Among men with BPH, the likelihood of acute urinary retention was greater in those taking an inhaled muscarinic antagonist (OR 1.81, 95% CI 1.46-2.24) and further increased among those taking both short and long-acting muscarinic antagonists compared with monotherapy (OR 1.84, 95% CI 1.25-2.71) or nonusers (2.69, 1.93-3.76).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A separate nested case-control study of 22,579 patients with COPD found an increased risk of acute urinary retention among those on inhaled muscarinic antagonists (adjusted odds ratio 1.40, 95% CI 0.99-1.98) compared with non-users [<a href="#rid75">75</a>]. The risk associated with <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> did not appear different from that associated with <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>.</p><p></p><p>On the other hand, reassuring data comes from these studies:</p><p class="bulletIndent1"><span class="glyph">●</span>The UPLIFT trial that randomly assigned approximately 6000 patients with COPD to <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> or placebo for four years included patients with BPH whose symptoms were controlled with treatment [<a href="#rid37">37</a>]. Urinary retention occurred more often in the tiotropium group than placebo (rate ratio 1.65, 95% CI 0.92-2.93), but the difference was not statistically significant [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 25 patients with COPD and BPH, use of <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> for months was not associated with any cases of acute urinary retention nor urinary parameters such as maximal flow rate (Q-max), average flow rate (Q-ave), postvoid residual urine volume (PVR), or bladder voiding efficiency (BVE) [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical trials with <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">aclidinium</a> have not noted an increased risk of acute urinary retention. (See <a class="local">'Aclidinium'</a> above.)</p><p></p><p>We are cautious when initiating inhaled muscarinic antagonists in patients with known BPH and advise patients to report any changes in urinary function.</p><p class="headingAnchor" id="H2561277121"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4649.html" rel="external">"Patient education: Chronic obstructive pulmonary disease (COPD) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4647.html" rel="external">"Patient education: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Parasympathetic activity regulates bronchomotor tone via the vagus nerve. Impulses from the vagus nerve lead to secretion of acetylcholine, which in turn acts through nicotinic and muscarinic cholinergic receptors on airway smooth muscle and tracheobronchial submucosal glands. (See <a class="local">'Physiology and pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The muscarinic receptors M1 and M3 on airway smooth muscle cells mediate the parasympathetic bronchoconstrictive effect of the vagus nerve  (<a class="graphic graphic_figure graphicRef58052" href="/z/d/graphic/58052.html" rel="external">figure 1</a>). M2 receptors are located on postganglionic nerves; activation of M2 receptors limits further production of acetylcholine and protects against bronchoconstriction mediated via the parasympathetic nerves. Theoretically, blocking M1 and M3 without M2 would optimize the bronchodilator effect. (See <a class="local">'Physiology and pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The inhaled muscarinic antagonists (also known as anticholinergic agents) interrupt vagal-induced bronchoconstriction. <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">Ipratropium</a> bromide is an inhaled quaternary ammonium that blocks all three muscarinic receptors (M1, M2, M3). <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">Tiotropium</a> bromide and other long-acting muscarinic antagonists (LAMAs) predominantly block the M1 and M3 receptors  (<a class="graphic graphic_table graphicRef79055" href="/z/d/graphic/79055.html" rel="external">table 1</a>). (See <a class="local">'Physiology and pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with COPD, <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> is superior to the beta-adrenergic agonists in both short- and long-term studies of acute bronchodilation and in long-term improvement in dyspnea and quality of life  (<a class="graphic graphic_figure graphicRef73667" href="/z/d/graphic/73667.html" rel="external">figure 4</a>). (See <a class="local">'Ipratropium'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When used in COPD, the combination of <a class="drug drug_general" data-topicid="8772" href="/z/d/drug information/8772.html" rel="external">ipratropium-albuterol</a> provides greater bronchodilation than either agent used alone. (See <a class="local">'Combination therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">Tiotropium</a>, a dry powder inhaler, is more long-acting than <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>, but does not have an acute bronchodilating effect. Nonetheless, in COPD, it provides superior long-term bronchodilation compared with ipratropium. It also reduces the frequency of exacerbations and hospitalizations, and improves dyspnea when compared with long-acting beta-agonists. (See <a class="local">'Tiotropium'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">Aclidinium</a>, administered by dry powder inhaler, is more long-acting than <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>, but shorter acting than <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>. At a dose of 400 mcg twice daily, it improves pulmonary function, health status, and dyspnea relative to placebo. <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">Glycopyrronium</a>  (<a class="graphic graphic_table graphicRef105687" href="/z/d/graphic/105687.html" rel="external">table 3</a>), <a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">umeclidinium</a> (in combination with vilanterol), and <a class="drug drug_general" data-topicid="119622" href="/z/d/drug information/119622.html" rel="external">revefenacin</a> (175 mcg/day by nebulization) are additional long-acting muscarinic antagonists (LAMAs) approved for maintenance treatment of COPD. (See <a class="local">'Umeclidinium'</a> above and <a class="local">'Aclidinium'</a> above and <a class="local">'Glycopyrronium'</a> above and <a class="local">'Revefenacin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite the minimal impact of <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> and <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> on heart rate and blood pressure, data are conflicting regarding possible adverse cardiovascular effects of these agents in patients with COPD. Based on available data, we believe that the potential for cardiovascular risk is extremely small and should be balanced against the <strong>known</strong> benefits. (See <a class="local">'Potential risks'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Integration of muscarinic antagonists into the management of COPD is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a> and  <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">"Stable COPD: Follow-up pharmacologic management"</a> and  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th, Hardman JG, Limbird LE, Molinoff PB, et al (Eds), McGraw-Hill, New York 1996. p.141.</li><li><a class="nounderline abstract_t">Courty, MA. Treatment of asthma. Edin Med J 1859; 5:665.</a></li><li><a class="nounderline abstract_t">Richardson JB. Nerve supply to the lungs. Am Rev Respir Dis 1979; 119:785.</a></li><li><a class="nounderline abstract_t">Barnes PJ. Cholinergic control of airway smooth muscle. Am Rev Respir Dis 1987; 136:S42.</a></li><li><a class="nounderline abstract_t">Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993; 52:521.</a></li><li><a class="nounderline abstract_t">Gross NJ. Ipratropium bromide. N Engl J Med 1988; 319:486.</a></li><li class="breakAll">Global Initiative for Chronic Obstructive Lung Disease. https://goldcopd.org/ (Accessed on February 28, 2022).</li><li><a class="nounderline abstract_t">Ziment I. Pharmacologic therapy of obstructive airway disease. Clin Chest Med 1990; 11:461.</a></li><li><a class="nounderline abstract_t">Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272:1497.</a></li><li><a class="nounderline abstract_t">Sin DD, Tu JV. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease. Thorax 2000; 55:194.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Ashutosh K, Bleecker ER, et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study. Am J Med 1986; 81:81.</a></li><li><a class="nounderline abstract_t">Chervinsky P. Concomitant bronchodilator therapy and ipratropium bromide. A clinical review. Am J Med 1986; 81:67.</a></li><li><a class="nounderline abstract_t">Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am J Med 1996; 100:11S.</a></li><li><a class="nounderline abstract_t">Chapman KR. Therapeutic approaches to chronic obstructive pulmonary disease: an emerging consensus. Am J Med 1996; 100:5S.</a></li><li><a class="nounderline abstract_t">In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105:1411.</a></li><li><a class="nounderline abstract_t">Gross N, Tashkin D, Miller R, et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998; 65:354.</a></li><li><a class="nounderline abstract_t">Gross NJ. Tiotropium bromide. Chest 2004; 126:1946.</a></li><li><a class="nounderline abstract_t">Tiotropium (Spiriva) for COPD. The Medical Letter on Drugs and Therapeutics 2004; 46:41.</a></li><li><a class="nounderline abstract_t">Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994; 150:1640.</a></li><li><a class="nounderline abstract_t">Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1136.</a></li><li><a class="nounderline abstract_t">Casaburi R, Briggs DD Jr, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000; 118:1294.</a></li><li><a class="nounderline abstract_t">van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55:289.</a></li><li><a class="nounderline abstract_t">Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143:317.</a></li><li><a class="nounderline abstract_t">Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD002876.</a></li><li><a class="nounderline abstract_t">Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217.</a></li><li><a class="nounderline abstract_t">Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19:209.</a></li><li><a class="nounderline abstract_t">Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124:1743.</a></li><li><a class="nounderline abstract_t">O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832.</a></li><li><a class="nounderline abstract_t">McNicholas WT, Calverley PM, Lee A, et al. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004; 23:825.</a></li><li><a class="nounderline abstract_t">Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; :CD009285.</a></li><li><a class="nounderline abstract_t">Anzueto A, Niewoehner DE, Leimer I, et al. A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium. Respir Med 2013; 107:1912.</a></li><li><a class="nounderline abstract_t">Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123:1441.</a></li><li><a class="nounderline abstract_t">Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; :CD009552.</a></li><li><a class="nounderline abstract_t">Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47.</a></li><li><a class="nounderline abstract_t">Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58:399.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125:249.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Celli B, Kesten S, et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010; 35:287.</a></li><li><a class="nounderline abstract_t">Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013; 185:393.</a></li><li><a class="nounderline abstract_t">Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012; 40:830.</a></li><li><a class="nounderline abstract_t">Kerwin EM, D'Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9:90.</a></li><li><a class="nounderline abstract_t">de la Motte S, Beier J, Schmid K, et al. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther 2012; 50:403.</a></li><li><a class="nounderline abstract_t">Aclidinium Bromide (Tudorza Pressair) for COPD. Med Lett Drugs Ther 2012; 54:99.</a></li><li><a class="nounderline abstract_t">Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012; 141:745.</a></li><li class="breakAll">Forest Research Institute FDA Advisory committee briefing document. Aclindinium bromide in chronic obstructive pulmonary disease NDA 02450. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM292624.pdf (Accessed July 24, 2012). p.50</li><li><a class="nounderline abstract_t">Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; :CD010509.</a></li><li><a class="nounderline abstract_t">Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs 2013; 73:741.</a></li><li><a class="nounderline abstract_t">D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011; 12:156.</a></li><li><a class="nounderline abstract_t">Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012; 40:1106.</a></li><li><a class="nounderline abstract_t">Hegde SS, Pulido-Rios MT, Luttmann MA, et al. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol Res Perspect 2018; 6:e00400.</a></li><li><a class="nounderline abstract_t">Quinn D, Barnes CN, Yates W, et al. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulm Pharmacol Ther 2018; 48:71.</a></li><li class="breakAll">Revefenacin. US Food and Drug Administration (FDA) approved product information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf (Accessed on November 13, 2018).</li><li class="breakAll">Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) https://clinicaltrials.gov/ct2/results?cond=&amp;term=NCT02512510&amp;cntry=&amp;state=&amp;city=&amp;dist=&amp;Search=Search (Accessed on November 13, 2018).</li><li class="breakAll">Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) https://clinicaltrials.gov/ct2/results?cond=&amp;term=NCT02459080&amp;cntry=&amp;state=&amp;city=&amp;dist=&amp;Search=Search (Accessed on November 13, 2018).</li><li><a class="nounderline abstract_t">Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 50:62.</a></li><li><a class="nounderline abstract_t">Cazzola M, D'Amato G, Guidetti E, et al. An M1-selective muscarinic receptor antagonist telenzepine improves lung function in patients with chronic obstructive bronchitis. Pulm Pharmacol 1990; 3:185.</a></li><li><a class="nounderline abstract_t">Ukena D, Wehinger C, Engelstätter R, et al. The muscarinic M1-receptor-selective antagonist, telenzepine, had no bronchodilatory effects in COPD patients. Eur Respir J 1993; 6:378.</a></li><li><a class="nounderline abstract_t">Shioya T, Kagaya M, Sano M, et al. Antimuscarinic effect of tiquizium bromide in vitro and in vivo. Eur J Clin Pharmacol 1996; 50:375.</a></li><li><a class="nounderline abstract_t">Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med 2004; 3:247.</a></li><li><a class="nounderline abstract_t">Ortiz S, Flach S, Caracta C, et al. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants. J Clin Pharmacol 2012; 52:819.</a></li><li><a class="nounderline abstract_t">Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:1439.</a></li><li><a class="nounderline abstract_t">Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006; 130:1695.</a></li><li><a class="nounderline abstract_t">Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166:333.</a></li><li><a class="nounderline abstract_t">Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149:380.</a></li><li><a class="nounderline abstract_t">Wang MT, Liou JT, Lin CW, et al. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study. JAMA Intern Med 2018; 178:229.</a></li><li><a class="nounderline abstract_t">Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009; 103:1421.</a></li><li><a class="nounderline abstract_t">Ogale SS, Lee TA, Au DH, et al. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010; 137:13.</a></li><li><a class="nounderline abstract_t">Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137:20.</a></li><li><a class="nounderline abstract_t">Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:948.</a></li><li><a class="nounderline abstract_t">Wise RA, Chapman KR, Scirica BM, et al. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. JAMA 2019; 321:1693.</a></li><li><a class="nounderline abstract_t">Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342:d3215.</a></li><li><a class="nounderline abstract_t">Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369:1491.</a></li><li><a class="nounderline abstract_t">Wise RA, Anzueto A, Calverley P, et al. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res 2013; 14:40.</a></li><li><a class="nounderline abstract_t">Stephenson A, Seitz D, Bell CM, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med 2011; 171:914.</a></li><li><a class="nounderline abstract_t">Afonso AS, Verhamme KM, Stricker BH, et al. Inhaled anticholinergic drugs and risk of acute urinary retention. BJU Int 2011; 107:1265.</a></li><li><a class="nounderline abstract_t">Vande Griend JP, Linnebur SA. Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia. Ann Pharmacother 2012; 46:1245.</a></li><li><a class="nounderline abstract_t">O'Connor AB. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009; 360:185.</a></li><li><a class="nounderline abstract_t">Miyazaki H, Suda T, Otsuka A, et al. Tiotropium does not affect lower urinary tract functions in COPD patients with benign prostatic hyperplasia. Pulm Pharmacol Ther 2008; 21:879.</a></li></ol></div><div id="topicVersionRevision">Topic 1450 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th, Hardman JG, Limbird LE, Molinoff PB, et al (Eds), McGraw-Hill, New York 1996. p.141.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of asthma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/110183" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nerve supply to the lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3310783" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cholinergic control of airway smooth muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8441331" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Muscarinic receptor subtypes in airways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2970009" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ipratropium bromide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2970009" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ipratropium bromide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205440" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pharmacologic therapy of obstructive airway disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7966841" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10679537" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2947465" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2947463" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Concomitant bronchodilator therapy and ipratropium bromide. A clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610712" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610718" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Therapeutic approaches to chronic obstructive pulmonary disease: an emerging consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181328" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9782217" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596697" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tiotropium bromide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tiotropium (Spiriva) for COPD</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7952627" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764302" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083677" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10722768" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16144890" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846642" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inhaled tiotropium for stable chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11866001" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11871363" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14605043" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15218994" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15218993" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25046211" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Tiotropium versus placebo for chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23969305" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12740259" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26391969" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114338" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12728159" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718448" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The role of long-acting bronchodilators in the management of stable COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18836213" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A 4-year trial of tiotropium in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717481" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23026438" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22441743" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22320148" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541745" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Aclidinium Bromide (Tudorza Pressair) for COPD</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903737" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy of aclidinium bromide 400μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903737" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy of aclidinium bromide 400μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25234126" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Aclidinium bromide for stable chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23677802" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22151296" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23060624" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29736245" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28987804" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28987804" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28987804" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28987804" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7886652" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2135223" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : An M1-selective muscarinic receptor antagonist telenzepine improves lung function in patients with chronic obstructive bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8472828" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The muscarinic M1-receptor-selective antagonist, telenzepine, had no bronchodilatory effects in COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8839659" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Antimuscarinic effect of tiquizium bromide in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15350163" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21628603" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18812535" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166984" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pooled clinical trial analysis of tiotropium safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12153966" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hospitalizations and mortality in the Lung Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794557" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29297057" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19556116" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19363211" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cardiovascular events associated with ipratropium bromide in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19592475" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cardiovascular safety of tiotropium in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19729663" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31063575" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21672999" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23992515" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Tiotropium Respimat inhaler and the risk of death in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23547660" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606096" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20880196" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Inhaled anticholinergic drugs and risk of acute urinary retention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851743" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19137624" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Tiotropium in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18992357" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Tiotropium does not affect lower urinary tract functions in COPD patients with benign prostatic hyperplasia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
